Teladoc’s third-quarter results were met with a significant positive market reaction, reflecting investor confidence in the company’s execution despite a year-over-year revenue decline. Management cited robust progress in its core strategic initiatives, particularly the rapid expansion of insurance-covered mental health sessions through BetterHelp and operational improvements within integrated care. CEO Charles Divita highlighted that “consolidated revenue came in near the upper end of our guidance range and adjusted EBITDA above guidance, with both segments contributing to the quarter’s performance.” The company also welcomed new CFO Mike Grasher, signaling a continued focus on financial discipline and operational efficiency.
Is now the time to buy TDOC? Find out in our full research report (it’s free for active Edge members).
Teladoc (TDOC) Q3 2026 highlights:
- Revenue $605.1 million vs S&P analysts’ estimates of $588.4 million (3.4% year-on-year decline, 2.8% beat)
- EPS (GAAP) -$0.15 vs analyst estimates of -$0.21 (30.8% beat)
- Adjusted EBITDA $79.36 million vs analyst estimates of $68.08 million (13.1% margin, 16.6% beat)
- Revenue guidance $592 million at the midpoint for Q4 2026, below analyst estimates of $596.6 million
- GAAP EPS guidance -$0.85 at the midpoint for the full year, beating analyst estimates by 4.5%
- EBITDA guidance $290 million at the midpoint for the full year, above analyst estimates of $278.6 million
- Operating margin -4.6%, up from -8.3% in the same quarter last year
- Market capitalization $1.59 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our top 5 analyst questions from Teladoc’s Q3 earnings call
- Allen Lutz (Bank of America) asked about the pace of onboarding therapists for BetterHelp’s insurance model. CEO Charles Divita explained the increase is due to investments in credentialing and evolving compensation programs, stating the company is “getting some scale benefit” and focusing on both national and local capacity.
- Richard Close (Canaccord Genuity) questioned the drivers behind better-than-expected cash pay performance and the impact of reduced advertising on guidance. Divita acknowledged ongoing downward pressure in cash pay but noted improved customer acquisition costs and a planned pullback in ad spending as major factors.
- Lisa Gill (JPMorgan) probed how Teladoc 1 will factor into 2027 bookings and client discussions. Divita described early client engagement and patient feedback as positive and expects Teladoc 1 to become more meaningful in 2027, with broader availability planned for that year.
- Sarah James (Cantor Fitzgerald) asked about integrated care margin dynamics and the impact of investments on future results. Divita and CFO Grasher explained that Q3 outperformance enables incremental investments, with margin expansion balanced against new growth initiatives and some seasonal factors like flu.
- Jessica Tassan (Piper Sandler) inquired about the sustainability of insurance reimbursement rates for BetterHelp and the implications for SG&A. Divita said rates have been consistent and that scaling insurance is expected to drive operating leverage, with a focus on balancing top- and bottom-line outcomes as the business pivots.
Catalysts in upcoming quarters
In the coming quarters, the StockStory team will focus on (1) tracking the ramp of insurance-covered sessions and therapist network expansion at BetterHelp, (2) monitoring adoption and client feedback on Teladoc 1 as the company targets broader rollout, and (3) assessing the scaling of hybrid care offerings in both the U.S. and international markets. Additionally, shifts in advertising strategy and integration of AI-powered tools will be important markers for operational progress.
Teladoc currently trades at $8.56, up from $6.85 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).
High-quality stocks for all market conditions
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
